Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

Key Inclusion Criteria:

• At least 18 years of age

• Have one of the following clinical diagnoses: schizophrenia or schizoaffectivedisorder, bipolar disorder, or major depressive disorder

• Have a clinical diagnosis of neuroleptic-induced TD

• Medication(s) for schizophrenia or schizoaffective disorder, bipolar disorder, ormajor depressive disorder and other protocol-allowed concurrent medications must beat a stable dose and expected to remain stable during the study

• Participants must be outpatients and have a stable psychiatric status

Key Exclusion Criteria:

• Have comorbid abnormal involuntary movement(s) (for example, Parkinsonism,akathisia) that is more prominent than TD

• Have an active, clinically significant unstable medical condition in the judgementof the investigator, or have any laboratory value outside the normal range that isconsidered by the investigator to be clinically significant at the screening visit